Red Flags
- Acute foot ulceration, infection, or new deformity in a diabetic patient with neuropathy — same-day multidisciplinary diabetic foot service; risk of limb loss[1]
- Asymmetric, rapidly progressive, or motor-predominant neuropathy — investigate for non-diabetic cause (CIDP, vasculitis, B12 deficiency, paraproteinaemia, drug toxicity, malignancy)[1]
- Concurrent mood disorder or suicidal ideation — psychiatric assessment alongside pain management; pain and depression compound[1]
- Opioid prescription for diabetic neuropathy — strongly discouraged; review and de-prescribe[1]
First-line treatment
Interventions
- Optimised glycaemic control[1]Type 1 DM — intensive control reduces incidence and progression. Type 2 DM — control modestly affects established painful neuropathy; combine with cardio-renal pillar therapy (SGLT2 inhibitor, GLP-1 RA)
- Foot care and protective offloading[1]Daily foot inspection, well-fitting shoes, avoid walking barefoot, podiatry follow-up; treat pre-ulcer signs urgently
- Choose initial agent across four equally effective classes[1]TCAs, SNRIs, gabapentinoids, or sodium channel blockers. Selection based on comorbidities, side-effect profile, cost, drug interactions; switch to a different class if inadequate response after 8 weeks at therapeutic dose
First-line drug therapy
| Drug | Class | Adult | Paediatric | Notes |
|---|---|---|---|---|
| Amitriptyline or nortriptyline[1] | Tricyclic antidepressant | Amitriptyline 10–25 mg PO at night; titrate to 75–150 mg as tolerated. Nortriptyline same range — better tolerated in elderly | — | First-line; useful with comorbid insomnia and depression; cardiac caution in older adults (ECG before higher dose); avoid in glaucoma, prostatic hypertrophy |
| Duloxetine[1] | Serotonin-norepinephrine reuptake inhibitor (SNRI) | 30 mg PO daily × 1 week then 60 mg daily; max 120 mg in some patients | — | First-line; useful with comorbid depression or anxiety; nausea on initiation, hepatic caution; avoid with MAOI |
| Venlafaxine extended-release[1] | SNRI | 37.5 mg PO daily; titrate to 150–225 mg/day | — | Alternative SNRI; monitor BP at higher doses |
| Pregabalin[1] | Gabapentinoid (α2δ ligand) | 75 mg PO BD; titrate to 150–300 mg BD as tolerated | — | First-line; renal dose adjustment; sedation, weight gain, peripheral oedema; concerns about misuse in some jurisdictions |
| Gabapentin[1] | Gabapentinoid | 300 mg PO night then 300 mg BD then 300 mg TDS over a week; usual 900–3600 mg/day in three divided doses | — | First-line; lower cost than pregabalin; renal dose adjustment; sedation and oedema common |
| Sodium channel blocker (lacosamide, oxcarbazepine, valproate selected cases)[1] | Sodium channel blocker | Lacosamide 50 mg PO BD; oxcarbazepine 150 mg PO BD; titrate | — | Alternative class with similar effect size; used when first-line classes fail or are contraindicated; cardiac and hyponatraemia monitoring per agent |
| Topical capsaicin 8% patch[1] | TRPV1 agonist (topical) | Single 30-minute application, can repeat every 90 days | — | Localised painful neuropathy; transient burning at application site; pre-treat with topical anaesthetic; specialist application |
| Topical lidocaine 5% patch[1] | Sodium channel blocker (topical) | Up to 3 patches applied to most painful area for up to 12 h/24 h | — | Localised pain only; minimal systemic absorption; safer in elderly with comorbidities |
Amitriptyline or nortriptyline[1]
Tricyclic antidepressant
- Adult
- Amitriptyline 10–25 mg PO at night; titrate to 75–150 mg as tolerated. Nortriptyline same range — better tolerated in elderly
- Paediatric
- —
First-line; useful with comorbid insomnia and depression; cardiac caution in older adults (ECG before higher dose); avoid in glaucoma, prostatic hypertrophy
Duloxetine[1]
Serotonin-norepinephrine reuptake inhibitor (SNRI)
- Adult
- 30 mg PO daily × 1 week then 60 mg daily; max 120 mg in some patients
- Paediatric
- —
First-line; useful with comorbid depression or anxiety; nausea on initiation, hepatic caution; avoid with MAOI
Venlafaxine extended-release[1]
SNRI
- Adult
- 37.5 mg PO daily; titrate to 150–225 mg/day
- Paediatric
- —
Alternative SNRI; monitor BP at higher doses
Pregabalin[1]
Gabapentinoid (α2δ ligand)
- Adult
- 75 mg PO BD; titrate to 150–300 mg BD as tolerated
- Paediatric
- —
First-line; renal dose adjustment; sedation, weight gain, peripheral oedema; concerns about misuse in some jurisdictions
Gabapentin[1]
Gabapentinoid
- Adult
- 300 mg PO night then 300 mg BD then 300 mg TDS over a week; usual 900–3600 mg/day in three divided doses
- Paediatric
- —
First-line; lower cost than pregabalin; renal dose adjustment; sedation and oedema common
Sodium channel blocker (lacosamide, oxcarbazepine, valproate selected cases)[1]
Sodium channel blocker
- Adult
- Lacosamide 50 mg PO BD; oxcarbazepine 150 mg PO BD; titrate
- Paediatric
- —
Alternative class with similar effect size; used when first-line classes fail or are contraindicated; cardiac and hyponatraemia monitoring per agent
Topical capsaicin 8% patch[1]
TRPV1 agonist (topical)
- Adult
- Single 30-minute application, can repeat every 90 days
- Paediatric
- —
Localised painful neuropathy; transient burning at application site; pre-treat with topical anaesthetic; specialist application
Topical lidocaine 5% patch[1]
Sodium channel blocker (topical)
- Adult
- Up to 3 patches applied to most painful area for up to 12 h/24 h
- Paediatric
- —
Localised pain only; minimal systemic absorption; safer in elderly with comorbidities
Safety-net
- Inspect feet daily including soles and between toes; report any blister, callus, or wound the same day — diabetic foot infection can deteriorate within hours[1]
- Avoid alcohol — it worsens neuropathy and interacts with many of the medications used[1]
- Never increase pain medication beyond prescribed dose without speaking to your clinician — many cause sedation and falls in older adults[1]
Referral criteria
- Atypical neuropathy (asymmetric, motor-predominant, rapidly progressive, autonomic-predominant)Neurology and electrophysiology[1]
- Refractory painful diabetic neuropathy after sequential trials of 2–3 different classesPain medicine specialist for adjuncts (high-dose capsaicin, transcutaneous electrical nerve stimulation, spinal cord stimulation in selected cases)[1]
- Diabetic foot ulcer, infection, or Charcot deformityMultidisciplinary diabetic foot team — same-day if active infection or deep ulcer[1]
- Comorbid depression or suicidal ideationMental health and pain medicine coordination[1]
Clinical summary
Stepwise pharmacologic and non-pharmacologic management of painful diabetic peripheral neuropathy in adults with diabetes.